8 results about "Signaling transduction" patented technology

The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.The invention further relates to complementary parts of such systems that work best in combination.Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters / sheaths / shafts to yield a robust assessment of cardiac performance.Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

The invention provides an application research of nano layered double hydroxides (LDH) for immunoregulation of interleukin-6 (IL-6) to promote liver regeneration, and based on the biomedical potential of the layered double hydroxide nano material, the action mechanism of the layered double hydroxides nano material in liver regeneration is systematically clarified. According to the application, a potential molecular mechanism of promoting liver regeneration by LDH is disclosed for the first time from the perspectives of immunoregulation and signal transduction, and a new theoretical basis and an experimental basis are provided for application of a nano material in tissue regeneration and liver function reconstruction. In the future, physicochemical properties and targeting of LDH can be further optimized, interaction with immune cells, signal transduction network remodeling and long-term safety of LDH can be deeply discussed in combination with a multi-omics technology and an in-vivo imaging means, and a direction is provided for developing novel immunoregulation type nano-drugs.

The present invention relates to a peptide specifically activating signal transduction by targeting fibroblast growth factor receptor (FGFR), an FGFR agonist comprising the peptide, a pharmaceutical composition for preventing or treating diseases associated with decreased FGFR activity, and a cosmetic composition. An FAP1 peptide according to the present invention is a potent FGFR-activating peptide, which exhibited an effective concentration similar to that of bFGF protein, and showed the ability to promote wound healing and support tissue remodeling in vivo. Considering specificity to FGFR and the ability to promote wound healing , FAP1 can be used as a cost-effective alternative to the bFGF protein in therapeutic fields.

The present application relates to the technical field of cellular immunotherapy, and particularly relates to a kind of targeting PSMA chimeric antigen receptor immune cells and preparation method and application thereof.A kind of targeting PSMA chimeric antigen receptor modified immune effector cell, the chimeric antigen receptor includes antigen binding domain, hinge region, transmembrane domain and signal transduction domain, and the antigen binding domain is anti-PSMA single-chain antibody.The chimeric antigen receptor modified immune effector cell provided in the present application can specifically recognize and combine the antigen binding domain of PSMA, and the prepared chimeric antigen receptor macrophage has specific killing effect on the target cells positive for PSMA protein, and can be used for preparing tumor drugs for treating or preventing PSMA positive.

There are disclosed compounds of the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and / or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

This invention provides an immunomodulatory factor, its preparation method, and its application. The immunomodulatory factor includes: Eotaxin-2, I-309, IL-12p40, IL-12p70, MIG, MIP-1a, TNF-α, AR, BDNF, bFGF, EGF-R, EG-VEGF, IGFBP-6, VEGF, NAP-2, PF4, Activin A, ANG-1, DAN, Follistatin, Galectin-7, ICAM-2, etc. The immunomodulatory factor can be used to prepare immunomodulators, cancer intervention agents, etc., and is of great significance for research on the mechanisms by which thymic mitochondria regulate anti-tumor immunity, including influencing immune cell metabolism, signal transduction, apoptosis, and immune escape.

Disclosed herein are compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases to a proximity of receptors of interest. This novel methodology, termed Receptor Inhibition by Phosphatase Recruitment (RIPR), represents a new approach to reducing and suppressing signal by receptors that signal through phosphorylation mechanisms. More particularly, the disclosure provides novel multivalent protein-binding molecules that specifically bind a cell surface receptor and antagonize the receptor signaling through recruitment of a phosphatase activity. Also provided are compositions and methods useful for producing such molecules, as well as methods for the treatment of diseases associated with the inhibition of signal transduction mediated by cell surface receptor.

This invention relates to methods and compositions for regulating the activity of ABCB5+ stem cells. The invention also relates to assays and reagents for manipulating and characterizing compounds that regulate ABCB5+ cell signal transduction.